StemCells, Inc. Announces Termination of Phase II Pathway

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data

NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ: STEM ) (the “Company”) today announced its decision to terminate the Company’s Phase II Pathway Study in spinal cord injury following an in-depth review of data from the study and after obtaining the concurrence of the study’s Interim Analysis Data Monitoring Committee (the “IA-DMC”).  While the results showed overall improvement in patients treated with the Company’s proprietary cells, the magnitude of the effect and the perceived trend of the effect over time did not justify continuing the study or exploring the variability in the initial patient observations, given the financial resources available to the Company.

Seventeen patients have already been dosed in the Pathway Study.  The first cohort of the Pathway Study, consisting of six patients, was designed to assess the safety, and preliminary signs of efficacy, of cell administration into the cervical cord and select the dose level for the 40-patient second cohort. The second cohort of the Pathway Study was a randomized, controlled and single-blinded arm of the trial in 40 motor complete patients.

The six-, nine- and twelve-month results from the first cohort of the Pathway Study revealed encouraging patterns of improvements from baseline, especially in the first six months of the study. This was confirmed separately by a review of the data by independent experts in spinal cord injury, who agreed that the overall results indicated evidence of biological activity. However, the Company observed in this cohort a declining trend in the magnitude of the effect in both strength and function at the twelve month time point. While the results at twelve months were still improved from baseline, this late variability led the Company to conduct an earlier‑than‑planned interim analysis of the Cohort II data.  The results of this interim analysis, which were reviewed by the Company as well as by the IA-DMC, showed differences in motor strength that favored the treatment group, but the magnitude of the effect led both the Company and the IA-DMC to conclude that achieving the primary endpoint objective of the Pathway Study would be unlikely. Based upon these findings, the Company has decided to terminate the study and close out operations.

“Despite the outcome of the Pathway Study reported above, the Company is proud of our team’s numerous accomplishments and successes to date,” said Dr. Stephen Huhn, Chief Medical Officer and VP of Clinical Research. “Data from earlier clinical trials involving the Company’s proprietary HuCNS-SC® human neural stem cells have demonstrated an early signal of biological activity in multiple disease indications. Our earlier Phase I/II clinical trial in chronic thoracic spinal cord injury showed measureable gains, while the Phase I/II clinical trial in geographic atrophy showed a positive safety profile and favorable preliminary efficacy. Additionally, a Phase I study in children with Batten’s disease showed that transplantation of the cells into the brain was safe and resulted in long term survival of the cells.”

Dr. Huhn continued, “Even in the Pathway Study, we believe we see a biological signal in many of the patients.  Equally important, the first cohort of the study also confirmed the safety of cell administration into the cervical cord. The collective human data we have generated across all of our studies reinforce our belief that our cells have an excellent safety profile and that there are neurological and retinal disorders with unmet need that may be helped by cell transplant. Unfortunately, the Company does not have the resources to implement changes in our development program to permit further investigation.”

“That we did not see significant recovery of motor functions in the Pathway Study is disappointing given the Company’s nearly complete restoration of motor and sensory functions with HuCNS-SC cells in spinal cord injured immunodeficient mice, the recovery of sensory responses in patients with thoracic spinal cord injury, and the many other encouraging clinical and preclinical studies with these cells,” added Dr. Irv Weissman, a Director and co-founder.  “Given the collective strength of past data with these cells, we sincerely hope others will pick up the many questions we have about the variability of results seen in the Pathway Study.  Naturally, over the next few weeks, we will endeavor to find a party able to continue the development of this very promising technology, which is so important not only for current and future patients with these devastating diseases, but also for the field of brain stem and progenitor cell therapies.” 

“We would like to thank the patients who participated in the Pathway Study as well as their families and caregivers. Spinal cord injury is one of the most devastating injuries to the central nervous system and any effort to help advance or investigate a potential therapy is worthwhile. The Company would also like to thank our clinical trial investigators and their teams, who have shared our mission in helping these patients. The Company will work with the clinical sites to suspend the trial activities and detailed information will be provided to patients in the trial regarding their participation,” concluded Dr. Huhn.

The Pathway Study

The Pathway Study was a single blind, randomized, controlled clinical trial investigating the use of the Company’s proprietary HuCNS-SC human neural stem cells for the treatment of chronic spinal cord injuries (SCI). Patients eligible for the study had complete loss of motor control below the level of injury, the most severe degree of SCI as defined by the American Spinal Injury Association Impairment Scale (AIS). Clinicians used both ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury) and GRASSP (Graded Assessment of Strength Sensibility and Prehension) measures to establish a pre-transplant baseline for each patient and to assess post-transplant progress. The goal of the Pathway Study was to demonstrate improved upper extremity motor function and fine motor skills.

Interim Analysis

In performing the interim analysis of Cohort II, an Interim Analysis Data Monitoring Committee consisting of three leading clinicians in the spinal cord injury field, reviewed the accrued data to date against specific clinically relevant criteria linked to achieving the statistically significant result for improving motor strength and function in treated patients. Following this analysis, the IA-DMC concluded that the data failed the futility criteria established for the interim analysis and recommended cessation of the study.  The Company took the IA-DMC’s recommendation under advisement in making its decision to terminate the Pathway Study.

Company to Initiate Orderly Wind Down

The Company also announced that, in light of the decision to terminate the Pathway Study, the Company’s available strategic alternatives and its current cash position, the Board of Directors approved a plan to wind down the Company.  As part of this process, the Company will evaluate opportunities to monetize its intellectual property, including data collected in its studies and trade secrets, as well as the transfer of its proprietary HuCNS-SC cells and other assets through a potential sale. The Company will not proceed with its earlier plans to conduct a rights offering, for which it had filed a registration statement with the SEC.

As of May 31, 2016, the Company had cash and cash equivalents of approximately $5.5 million. The Company cannot determine with certainty the amount of any liquidating distribution to its stockholders and it is possible that there will be no liquidating distribution to stockholders. The amount of any cash distributed to its stockholders will depend upon, among other things, the Company’s current liquid assets offset by its known and unknown liabilities as well as operating expenses associated with the wind down.

“We are extremely disappointed with the results of our Pathway Study, which we had hoped to be the first clinical program involving cellular transplantation to meaningfully improve motor function in patients with chronic spinal cord injury,” said Dr. Ian Massey, President and Chief Executive Officer. “However, we continue to feel immense pride over the contributions we have made to the stem cell research field, and we are confident that the progress we made will be instrumental in future studies in this area.  The other directors and I are also very appreciative of our employees for their hard work and dedication to our mission, and thankful to the scientific community and our stockholders for their support through the years.”

ISSCR 2016 Annual Meeting

The Company will attend the 14 th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in San Francisco, California, on June 23.  The Company will present Cohort I data from the Pathway Study and its interim analysis outcome. 

Further information about StemCells, Inc., including its preclinical and clinical studies, is available at http://www.stemcellsinc.com .

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the future business operations of   StemCells, Inc.   (the "Company"), the prospect for the successful divestiture of any of the Company’s assets, the possibility of a liquidating distribution to Company stockholders, and the ability of the Company to pay its creditors and successfully complete an orderly wind down. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including risks whether the   FDA   and other applicable regulatory agencies will support the Company’s plans to discontinue its currently active clinical studies; uncertainty as to whether HuCNS-SC cells will prove safe and not cause tumors or other adverse side effects in the patients enrolled in the Company’s clinical studies; uncertainties whether the Company’s stock will continue to be listed on any securities exchange; litigation uncertainties; uncertainties regarding the Company’s plans to wind down operations; uncertainties regarding the validity, enforceability and potential value of the Company's patents; uncertainties as to whether the Company will be able to continue to pay its obligations in the ordinary course of business as they come due; and other factors that are described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended   December 31, 2015.

CONTACT: CONTACT: INVESTOR CONTACT: Greg Schiffman StemCells, Inc. Chief Financial Officer (510) 456-4128 Robert Haag Managing Director IRTH Communications STEM@irthcommunications.com 1-866-976-4784 MEDIA CONTACT: Lena Evans Russo Partners (212) 845-4262 Kelly Sullivan / Eric Brielmann Joele Frank Wilkinson Brimmer Katcher 212-355-4449

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 177

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 231

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 459

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 23

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 54

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 46

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 373

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 142

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading

Top 5 Most Recently Viewed Articles

Insigneo Welcomes Esteban Diaz to Enhance Wealth Management

Updated Category News Views 159

Insigneo Strengthens Its Wealth Management Team Insigneo, a prominent name in wealth management, proudly announces the addition of Esteban Diaz as Senior Vice President. This significant recruitment is part of the firm’s ongoing commitment to enhancing its network, particularly in serving high-net-worth clients in the Latin American region. About Esteban Diaz's...

Continue Reading
Exploring RBC Bearings: A Five-Year Investment Journey

Updated Category News Views 172

RBC Bearings: A Strong Investment Over Time RBC Bearings has proven to be a formidable player in the market, showcasing impressive performance over the last five years. With an average annual return of 18.74%, any investment made during this period would have reaped considerable rewards. The Growth of a $1000 Investment Imagine if you had decided to invest $1000 in RBC...

Continue Reading
ANI Pharmaceuticals Enhances Ophthalmology Strategy with Experts

Updated Category News Views 227

ANI Pharmaceuticals Launches FutureVision Advisory Council In a strategic move to bolster its ophthalmology and retina franchise, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has established the FutureVision Advisory Council. This dedicated council aims to guide the ongoing innovations within ANI's Rare Disease portfolio, focusing particularly on ophthalmological care....

Continue Reading
Unlocking Financial Freedom: The CESUR Mining Game Changer

Updated Category News Views 99

Understanding CESUR Mining and Its Impact CESUR Mining is quickly becoming a significant player in the world of cryptocurrency. This innovative platform enables users to tap into the potential of cloud mining, allowing them to earn passive income without the need for technical knowledge or constant monitoring. Established with the vision to simplify the mining process,...

Continue Reading
Understanding Nvidia's Role in the S&P 500 Market Dynamics

Updated Category News Views 204

Nvidia's Influence on the S&P 500 Market The stock market can be quite a wild ride, with swings that can astonish even the most experienced investors. Recently, stocks started off relatively flat but soon encountered volatility, leading to a significant rally largely fueled by news surrounding Nvidia. This surge prompts important questions about how the S&P 500 will...

Continue Reading